Semaglutide not working? What the evidence says about poor response

What's this video probably claiming?

A chiropractor with a DC credential is telling 15,000-plus viewers that their semaglutide results might be suboptimal, and probably offering a diagnosis for why. Based on the caption framing, the video likely runs through reasons people "plateau" or underperform on GLP-1 therapy: inadequate dose titration, poor diet quality, not enough protein, sleep issues, or possibly a pitch for adjunct supplements or services. DC-credentialed creators frequently blend legitimate lifestyle advice with out-of-scope clinical commentary. The phrase "results you should be getting" implies there's a standard outcome being missed, which is a reasonable premise, but the explanation for why is where things tend to go sideways. This fact-check treats the video as a topical analysis pending full transcript review. The claims below reflect what research actually shows about variable semaglutide response, not assumptions about this specific creator's intent.

What does the science actually show?

Semaglutide response is genuinely variable and the data bears that out. In the STEP 1 trial (Wilding et al., 2021, NEJM), participants on 2.4 mg weekly semaglutide lost an average of 14.9% body weight over 68 weeks, but that's a mean. The distribution matters: roughly 30% of participants lost less than 10% body weight, and a meaningful subset lost under 5%. A 2022 analysis in Obesity (Almandoz et al.) identified baseline insulin resistance, sleep apnea severity, and medication interactions as independent predictors of blunted response. Adherence is also huge. The STEP trials used supervised titration schedules; real-world adherence is messier. A 2023 retrospective in Diabetes, Obesity and Metabolism found that patients who skipped more than two doses in a 12-week window lost roughly 40% less weight than adherent counterparts. None of this means something exotic is wrong. It usually means dose, diet, or duration need adjustment.

Where does the social media noise diverge from clinical reality?

The biggest divergence is the implied urgency that something is broken. Most creators framing this topic suggest the fix is a supplement stack, a detox protocol, or a service they happen to offer. The actual clinical literature points somewhere more boring. A 2023 paper in the Journal of Clinical Endocrinology and Metabolism (Kushner et al.) noted that patients who hadn't reached target dose (2.4 mg for weight management) were frequently labeled non-responders prematurely. Many simply hadn't completed the standard 16-to-20-week titration. Social media compresses timelines aggressively. Viewers expect 10% weight loss in eight weeks because that's what the show reel looks like. Another common noise signal is the suggestion that compounded semaglutide performs identically to FDA-approved Wegovy or Ozempic. It doesn't have equivalent regulatory scrutiny, and the FDA has flagged compounded versions specifically. Any creator conflating the two is giving you incomplete information regardless of their credential level.

What should you actually know?

If you're on semaglutide and underwhelmed by results, the checklist is straightforward before concluding the drug isn't working. First, confirm you're at therapeutic dose. The 0.25 mg starting dose is not a treatment dose, it's a tolerance ramp. Second, look at protein intake. Research from Bianco et al. (2022, Nutrients) suggests high-protein diets preserve lean mass during GLP-1-induced caloric restriction, which affects how results look on the scale. Third, sleep is not optional: short sleep duration increases ghrelin and counteracts appetite suppression, per a 2023 review in Obesity Reviews. Fourth, some medications including certain antidepressants, corticosteroids, and antipsychotics blunt GLP-1 efficacy through insulin resistance pathways. That conversation belongs with a prescribing clinician, not a TikTok comment section. A DC is not licensed to prescribe, adjust, or clinically evaluate your semaglutide response, and any advice crossing into those areas should be verified with your actual prescriber.